<DOC>
	<DOCNO>NCT01042600</DOCNO>
	<brief_summary>In study , newborn baby respiratory distress syndrome ( RDS ) , receive oxygen via nasal CPAP , need surfactant treatment randomize standard delivery surfactant via endotracheal tube airway ( inserted pre-medication pain ) , surfactant delivery via laryngeal mask airway ( LMA ) . The intent remove airway return baby nasal CPAP , surfactant give . The primary outcome measure rate failure initial surfactant therapy . Standardized failure criterion reach : ) early , baby unable place back CPAP ( need mechanical ventilation ) , b ) late , baby require retreatment surfactant within 8 hour 2 dos surfactant . The objective protocol reduce need endotracheal intubation mechanical ventilation preterm neonates RDS need rescue surfactant therapy instill surfactant though LMA , achieve comparable efficacy surfactant treatment . The hypothesis surfactant treatment LMA decrease proportion baby RDS require mechanical ventilation subsequent intubation , compare standard surfactant treatment follow sedation endotracheal intubation .</brief_summary>
	<brief_title>Randomized Controlled Trial Surfactant Delivery Via Laryngeal Mask Airway ( LMA ) Versus Endotracheal Intubation</brief_title>
	<detailed_description>Respiratory Distress Syndrome ( RDS ) due deficiency lung surfactant common preterm newborn . Early treatment surfactant improve oxygenation , reduces need subsequent mechanical ventilation , decrease incidence pulmonary air leak chronic lung disease also reduce mortality extremely premature newborn . Optimal treatment RDS include surfactant therapy avoidance invasive mechanical ventilation use nasal continuous positive airway pressure ( NCPAP ) . The current standard method surfactant delivery require tracheal intubation least brief positive-pressure ventilation . Tracheal intubation cause pain lead vagal-mediated physiologic instability neonate ; therefore , premedication morphine atropine routinely practice setting . However , premedication morphine often increase respiratory depression , require sustain mechanical ventilation . The Laryngeal Mask Airway ( LMA ) commercially available , less invasive artificial airway need insert trachea ; FDA-approved use neonate , preliminary data suggest use surfactant administration . The main objective study protocol reduce need endotracheal intubation mechanical ventilation preterm neonates mild moderate RDS needing rescue surfactant therapy instill surfactant though LMA . A second objective compare efficacy surfactant administer via LMA versus endotracheal tube ( ETT ) decrease severity RDS . Additionally , evaluate safety surfactant administration via LMA . The primary hypothesis surfactant treatment via LMA approach decrease proportion baby RDS require mechanical ventilation subsequent intubation , compare standard surfactant administer ETT group . This randomize controlled trial include baby mild-to-moderate RDS , 4 48 hour age , gestational age 29 0/7 36 6/7 week , treat NCPAP ≥ 5 cm H2O FiO2 0.30 0.60 least 2 hour maintain SpO2 88-95 % , informed consent . Exclusion criterion weight &lt; 1000 g , airway anomaly , pulmonary air leak , craniofacial cardiothoracic malformation . After informed consent obtain , baby randomly assign ( seal , opaque , consecutively numbered envelope ) , `` ETT '' `` LMA '' . The `` ETT '' group manage accord current practice surfactant therapy ( endotracheal intubation follow premedication atropine + morphine ) , whereas `` LMA '' group pre-medicated atropine LMA insertion surfactant administration . Both group receive Infasurf ( 3mL/kg ) instill 2 aliquot via respective airway , follow PPV least 5 minute . The artificial airway remove patient return NCPAP 15 minute , spontaneous respiration adequate . Indications surfactant re-dosing mechanical ventilation equivalent group . Babies continue initiate assist ventilation via ETT follow occurs : - Persistent apnea ; - Severe retraction ; - Inability wean FiO2 &lt; 60 % Criteria re‐dosing surfactant : 1 . Within 8 hour first dose surfactant ( early re‐dosing ) : - FiO2 20 % high baseline FiO2 , exclude obvious cause respiratory insufficiency pneumothorax . If early re‐dosing surfactant need patient either group , dose administer via ETT ( i.e. , LMA patient intubate , receive dose surfactant via ETT ) 2 . Beyond 8 hour first dose surfactant ( late re‐dosing ) : - FiO2 ≥ 60 % , ; - FiO2is ≥ 30 % associate worsen clinical sign RDS . If late re‐dosing need patient LMA group , use LMA permit second dose . In ETT group , dose give via ETT . Primary Outcome Measures : Rate failure early surfactant rescue therapy 2 group , use follow criterion differentiate early late failure : - Criteria early failure ( within 1 hour ) : 1 . The need mechanical ventilation within 1 hour surfactant therapy . 2 . Use Narcan avoid mechanical ventilation surfactant therapy . - Criteria late failure ( beyond 1 hour ) : 1 . Sustained FiO2 &gt; 0.60 maintain target SpO2 2 . Second dose surfactant within 8 hour first dose . 3 . More 2 dos surfactant . Babies FiO2 adjust maintain SpO2 88-95 % , per current practice . Other aspect wean ventilatory support manage clinician ' preference .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Newborn</mesh_term>
	<mesh_term>Respiratory Distress Syndrome , Adult</mesh_term>
	<mesh_term>Atropine</mesh_term>
	<mesh_term>Pulmonary Surfactants</mesh_term>
	<criteria>Mildtomoderate RDS Postnatal age 4 48 hour Gestational age 29 0/7 36 6/7 week Treated nasal CPAP ≥ 5 cm H2O FiO2 0.30 0.60 least 2 hour maintain SpO2 8895 % Informed consent Weight &lt; 1000 g Airway anomalies Pulmonary air leak Craniofacial cardiothoracic malformation</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>48 Hours</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>Respiratory distress syndrome</keyword>
	<keyword>Surfactant</keyword>
	<keyword>Tracheal intubation</keyword>
	<keyword>Laryngeal mask airway</keyword>
	<keyword>Newborn</keyword>
</DOC>